8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  December 30, 2005

Enpath Medical, Inc.

(Exact name of registrant as specified in its charter)

Minnesota

(State or Other Jurisdiction of Incorporation)

0-19467	41-1533300
(Commission File Number)	(IRS Employer Identification No.)
15301 Highway 55 West
Plymouth, Minnesota	55447
(Address of Principal Executive Offices)	(Zip Code)

(763) 559-2613

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1               Registrant’s Business and Operations

Item 1.01               Entry into a Material Definitive Agreement

Compensation of Directors

On December 30, 2005, the Board of Directors of Enpath Medical, Inc. adopted a resolution amending the Enpath Medical, Inc. 1999 Non-Employee Director and Medical Advisory Board Stock Option Plan (the “Plan”).  The Plan has provided that each non-employee director is entitled to receive the following: (i) an initial grant of a non-statutory stock option to purchase 15,000 shares;  (ii) a grant of a non-statutory stock option to purchase an additional 18,000 shares on the third anniversary of the initial option grant; and (iii) a grant of a non-statutory stock option to purchase an additional 21,000 shares on the sixth anniversary of the initial grant and each three year anniversary thereafter.

The Board determined that the granting of options to directors at three-year intervals on the anniversary of each director’s initial election to the Board was resulting in unequal treatment of directors, dependant upon the time the director joined the Board, and decided to move to a system of annual grants.  The Board had delayed the granting of the 21,000-share option otherwise due to a director on October 21, 2005 while it studied this issue.  On December 30, 2005 the Board adopted a resolution amending the Plan as follows:

•Effective at the 2006 Annual Meeting of Shareholders of Enpath Medical, Inc., each non-employee director will be granted an option to purchase 5,000 shares.  The option will be issued on the Monday following the annual Shareholder Meeting at a price equal to the fair market value on that date.  Options will vest 100% 330 days after issuance and will expire eight years after the date of issuance, subject to early termination one year after the person ceases to serve as a director.

•In order to create an effective transition to the new program, non-employer directors that otherwise would be entitled to a full three year grant prior to the 2006 Annual Meeting would receive a grant equal to the pro rata portion of the grant that the non-employee director would otherwise have received had the existing program remained in effect.

•Upon the granting of the new options for 5,000 shares at the 2006 Annual Shareholders Meeting, unvested options held by non-employee directors would be cancelled and the old program of three-years grants would be discontinued.

The amendment of the Plan will be presented for shareholder approval at the 2006 Annual Meeting.

Section 8 Other Events

Item 8.01 Other Events

On January 6, 2005, Enpath Medical, Inc. announced that it had received CE Mark approval from the European Union to market its steerable sheath.  The Company had received United States Food and Drug Administration clearance in July 2005.  The steerable sheath features distal tip deflection to aid in the precise placement of devices such as cardiac ablation catheters and peripheral stent

2

delivery catheters.  A copy of the January 6, 2006 press release is furnished as Exhibit 99.1 to this Form 8-K

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit 99.1Press release dated January 6, 2006, regarding GE Mark Approval for Steerable Sheath

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENPATH MEDICAL, INC.
Dated: January 6, 2006	By:	/s/ James D. Hartman
		James D. Hartman
		Chief Executive Officer

3

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE	Approved By:	Jim Hartman (763) 577-2212 Enpath Medical, Inc.
	Contacts:	Investors EVC Group Doug Sherk (415) 896-6820 Jennifer Beugelmans (415) 896-6820

January 6, 2006

Enpath Medical Receives CE Mark Approval for Steerable Sheath

Approval Clears Pathway for Launch into European Electrophysiology Market

MINNEAPOLIS—Enpath Medical Inc. (Nasdaq: NPTH) announced today that it has received CE Mark approval from the European Union to market its steerable sheath, a tool that facilitates the placement of interventional devices in the peripheral, coronary and neurovascular systems.  This approval clears the way for the Company’s distribution partner Bard Electrophysiology, a division of C.R. Bard, to launch the steerable sheath in Europe for electrophysiology (EP) applications.

“With the U.S. Food and Drug Administration (FDA) clearance received in July, 2005, the European Union’s approval positions Enpath’s innovative steerable sheath for distribution in the two largest electrophysiology markets in the world,” said Jim Hartman, Chairman and Chief Executive Officer of Enpath Medical.

Enpath’s steerable sheath features distal tip deflection to aid in the precise placement of such devices as cardiac ablation catheters and peripheral stent delivery catheters. “The EP market is the first of a variety of clinical applications that can benefit from the use of our steerable sheaths,” Mr. Hartman added.  “We are particularly excited by the potential for our proprietary steerable sheath technology to be used in the delivery of carotid artery stents and other peripheral vessel interventions, as well as for precision placement of implantable leads, and we are continuing to develop the device for these indications.”

About Enpath Medical

Enpath Medical, Inc., headquartered in Plymouth, Minnesota, is a leader in the design, development, manufacture and marketing of percutaneous delivery systems and stimulation leads technologies.  Its products include venous vessel introducers, epicardial and endocardial stimulation leads, safety needles and other products for use in pacemaker, defibrillator, catheter and infusion port procedures as well as neuromodulation and hearing restoration markets.  Its products are sold worldwide through partnering relationships with other medical device companies.